CAMBRIDGE, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of SAGE, will provide a corporate presentation at the 34^th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. PT (2:30 p.m. ET) on Monday, January 11, 2016, in San Francisco.

A live webcast of the presentation can be accessed on the investor page of SAGE's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on SAGE's website following the conference.

About Sage Therapeutics

Sage Therapeutics (NASDAQ:SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.

Investor Contact:
Paul Cox, Sage Therapeutics
paul.cox@sagerx.com
617-299-8377

Media Contact:
Dan Budwick, Pure Communications
dan@purecommunicationsinc.com
973-271-6085

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.